Our study revealed that addition of chemotherapy to PD-1 inhibitors did not improve OS or PFS compared with PD-1/PD-L1 inhibitor alone for NSCLC patients as second-line and later therapy. Here, CD274 is linked to non-small cell lung carcinoma.